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Abstract
Background: Insulin is the drug of choice in the management of diabetes mellitus (DM). About 76
% of diabetic patients suffer from gastrointestinal (GI) disorders. Therapy of DM with insulin
primarily involves lowering of elevated blood glucose levels. Hence, on any organ in addition to
insulin's effect, hypoglycaemic effect also prevails. A systematic study exploring the effect of insulin
on small intestinal transit in normal laboratory animals is lacking. Hence, in the present study, the
possible effect of insulin with or without associated hypoglycaemia on small intestinal transit in
normal mice was examined.
Results: Insulin in all the doses tested (2 µ, 2 m and 2 U/kg) elicited a significant acceleration of
SIT. The lower doses of insulin (2 µ and 2 m U/kg) produced significant acceleration of SIT and
were associated with normal blood glucose levels. However, the highest dose of insulin (2 U/kg)
produced an acceleration of SIT that was associated with significant fall in blood glucose levels.
Further, the 2 m and 2 U doses of insulin significantly elevated serum insulin and C-peptide levels.
Conclusion:  Insulin at the lowest dose produced an acceleratory effect on SIT that was
independent of blood glucose and serum insulin levels in normal mice.
Background
Diabetes Mellitus (DM) is a major chronic metabolic dis-
order affecting a large portion of population world wide
[1]. The diagnosis as well as the progression/remission of
DM are usually based on evaluation of biochemical
parameters viz., blood glucose, serum insulin and C-pep-
tide levels [2]. Assessment of serum insulin level in newly
diagnosed DM is helpful in deciding about the type of oral
hypoglycaemic agent to be prescribed [3]. Since the ther-
apy is for life time, the probability of development of
complications is more [4]. Complications involving the
enteric neuropathy causes considerable morbidity in
patients with long standing insulin-dependent diabetes
with poor glucose control and peripheral neuropathy
[5,6]. About 76% of DM patients suffer from gastrointes-
tinal symptoms [7]. These symptoms include gastropare-
sis, abdominal pain, diarrhoea, fecal incontinence and
constipation [8]. Motility studies of small intestine in dia-
betes are not extensive and available reports are contradic-
tory to one another [6,9]. In addition, the small intestine
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is generally considered as the main site of drug absorption
[10]. Patients with diabetic diarrhoea will have less time
for absorption of drugs taken orally [4].
Insulin is the drug of choice in controlling hyperglycaemic
state in Type 1 and sometimes for Type 2 diabetes [4].
Insulin has been reported to increase the gastric emptying
through hypoglycaemic effect [11]. Different segments of
GI tract are regulated by independent or different mecha-
nisms [10]. It is well known that insulin therapy primarily
involves reduction in blood glucose levels [4]. Hence on
any organ, in addition to hypoglycaemic effect, insulin's
effect may also prevails. A systematic study exploring the
effect of insulin on small intestinal transit in normal lab-
oratory animals is lacking. Therefore, we propose to study
the effect of insulin on small intestinal transit by using
Table 1: Effect of exogenous insulin administration on blood glucose (BG), serum insulin, C-peptide levels and small intestinal transit 
(SIT) in normal mice
Treatment Insu-
lin (U/kg;sc)a
Blood glucose levels %SITe Serum insulin 
levelsf (µU/ml)
Serum C-pep-
tide levelsg (ng/
ml)
Initial (mg/dL)b Final (mg/dL)c % Changed
Vehicle 70.66 ± 5.97 71.66 ± 5.93 101.96 ± 5.40 47.47 ± 3.22 32.62 ± 6.83 0.250 ± 0.01
2 µ 188.8 ± 29.73 198.8 ± 14.68 110.9 ± 10.65 68.43 ± 3.59** 55.18 ± 2.9 0.271 ± 0.01
2 m 128.16 ± 8.07 123.33 ± 13.62 94.88 ± 6.43 61.53 ± 4.42* 144.74 ± 13.43** 0.395 ± 0.02**
2 135.66 ± 8.76 53.66 ± 3.38 41.27 ± 5.60** 73.08 ± 2.18** 178.66 ± 12.23** 0.470 ± 0.01**
Each value represents the mean ± SEM (n = 6)
*P < 0.05; **P < 0.01 as compared with vehicle treated group
a Insulin administered (s.c) 50 min before blood glucose/SIT estimation
b Initial blood glucose levels were estimated before insulin/vehicle administration
c Final blood glucose levels were estimated 50 min after insulin/vehicle administration (time coinciding with SIT determination)
d % change (in blood glucose levels) obtained from any alteration in final BG value from initial BG level of each animal
e Values are % SIT considering the total length of the intestine as 100, SIT was determined 50 min after insulin administration
f Independent blood samples were collected at the time coinciding with SIT measurement for the measurement of serum insulin levels
g Independent blood samples were collected at the time coinciding with SIT measurement for the measurement of C-peptide levels
Experimental design carried out to study the effect of insulin administration on small intestinal transit (SIT) in normal mice Figure 1
Experimental design carried out to study the effect of insulin administration on small intestinal transit (SIT) in normal mice.
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varied doses in normal mice. This may provide an experi-
mental evidence for the unexplained relief of gastrointes-
tinal complications in DM when treated with insulin.
Results
Effect of insulin administration on small intestinal transit, 
blood glucose, serum insulin and C-peptide levels
Insulin administration at lower doses (2 µ and 2 m U/kg)
did not alter blood glucose levels significantly but pro-
duced a significant acceleration of SIT (P < 0.01) (Table
1). However, the higher dose (2 U/kg) produced an accel-
eration of SIT that was associated with a profound fall in
blood glucose levels (P < 0.01). Insulin at all the three
doses elevated serum insulin and C-peptide levels but the
statistical significance was achieved only at 2 m or 2 U
dose.
Effect of insulin administration on % change in SIT and 
blood glucose levels
Insulin administration with lower doses (2 µ and 2 m U/
kg) produced significant acceleration of SIT and were
associated with normal blood glucose levels. However the
higher dose of insulin (2 U/kg) produced an acceleration
of SIT that was associated with a significant fall in blood
glucose levels (P < 0.01) (Fig 2).
Effect of insulin administration on % change in SIT and 
serum insulin level
In contrast to glycaemic states, with all the doses of insu-
lin administration a positive relationship between the
changes in SIT and insulinemic states was recorded (Fig
3). While insulin in all the doses tested produced similar
degree of acceleration of SIT, the effect on serum insulin
levels was noticed to be dose related.
Discussion
Our study with insulin administration demonstrates a
novel finding that lower doses of insulin significantly
accelerated small intestinal transit without altering blood
glucose levels (Table 1). Generally, the parenteral admin-
istration of insulin produces maximal fall in blood glu-
cose levels within 20–30 min [4]. Therefore, to study the
effect of insulin and associated fall in blood glucose levels
on intestinal transit, the charcoal meal was administered
Effect of insulin administration on % change in small intestinal transit (SIT)and blood glucose (BG) levels in normal mice Figure 2
Effect of insulin administration on % change in small intestinal transit (SIT)and blood glucose (BG) levels in normal mice. Values 
are expressed in terms of % change (increase or decrease) when compared with respective vehicle treated group. *P < 0.05; 
**P < 0.01 when compared with respective vehicle treated group.
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30 min after insulin administration. We used varied doses
of insulin to avoid or sustain the hypoglycaemic effect,
and to explore an inherent effect of insulin on SIT. Bulatao
and Carlson [14] observed the hypoglycaemic effect of
insulin in dogs was associated with an increase in the
height and frequency of gastric contractions and gastric
tonus. These effects depend on blood glucose levels [15].
Later studies indicated the acceleration of gastric empty-
ing [11] and other parts of intestine [16] were due to the
hypoglycaemic effect of insulin. In our experiment, blood
glucose levels were not affected with lower doses of insu-
lin (2 µ and 2 m U/kg) but produced a significant acceler-
ation of SIT. However, the higher dose of insulin (2 U/kg)
produced an acceleration of SIT that was associated with a
significant fall in blood glucose levels (P < 0.01) (Fig 2).
This may indicate that an indirect role for hypoglycaemic
state in acceleratory effect of insulin on SIT at the high
dose. Hence, we suggest that blood glucose levels do not
play a role at least in lower doses of insulin in accelerating
SIT.
Insulin acts indirectly on stomach through vagus nerve to
increase the gastric emptying [17]. In fact, it was empha-
sized that insulin injection could be used as a challenge to
test the functional integrity of vagus fibers to the stomach.
At one time, insulin effect on gastrointestinal (GI) motil-
ity was recommended as a model to compare prokinetic
drugs on GI motility, which is comparable to metoclopra-
Effect of insulin administration on % change in small intestinaltransit (SIT) and serum insulin (Ser Ins) levels in normal mice Figure 3
Effect of insulin administration on % change in small intestinaltransit (SIT) and serum insulin (Ser Ins) levels in normal mice. Val-
ues are expressed in terms of % change when compared with respective vehicle treated group. *P < 0.05; **P < 0.01 when 
compared with respective vehicle treated group.
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mide [18,19]. In addition, it was also reported that insulin
may have a permissive role in maintaining basal pattern
motility in the sheep intestine [20]. Some contrasting
reports are also available about production of depressant
effect on GI motility by releasing norepinephrine in rats
[21,22] and some attributed this inhibitory effect due to
hyperpolarization of smooth muscle [23] or to the phenol
content of commercial insulin [24]. Moreover, these
observations were recorded at higher concentrations of
insulin [14,18,20].
To rule out the influence of endogenous insulin on SIT,
we felt it is necessary to measure the serum insulin levels.
We observed that serum insulin levels were not altered
with the lowest dose of insulin (2 µU/kg). But with the
higher doses of insulin (2 m and 2 U/kg), the serum insu-
lin levels were significantly elevated (P < 0.01) (Fig 3).
These findings indicate that exogenously administered
insulin is solely responsible for significant acceleration of
SIT, but with the higher doses of insulin elevated endog-
enous insulin levels produced cannot be ruled out in
acceleration of SIT. The elevated serum insulin levels
observed with higher doses of insulin might be due to
insulin administration itself or a reflex release of endog-
enous insulin from the pancreas. Garvey et al [25]
reported about an improvement of endogenous insulin
secretion after exogenous insulin injection. There is also a
clinical evidence indicating that intensive insulin treat-
ment in Type 2 diabetes improve β-cell function [26].
These reports also support a view that exogenous insulin
administration may have a reflex action over the secretion
of insulin from pancreas in healthy animals.
To further elucidate the role of endogenous insulin levels
on SIT with higher doses of insulin, we evaluated C-pep-
tide of insulin levels. C-peptide is released in equimolar
ratio with insulin from islet cells and is not extracted by
liver [27]. Hence, the C-peptide measurement reflects the
absolute status of endogenous insulin production. Nor-
mally the C-peptide level is expected to come down by
supplementation of insulin. Surprisingly, we noticed that
C-peptide levels in serum were significantly elevated with
higher doses of insulin administration (P < 0.01) (2 m
and 2 U/kg) (Table 1). In this animal model, the above
observation further confirms the view that higher doses of
exogenously administered insulin reflexly stimulate the
synthesis of insulin which resulted in release of C-peptide.
These findings strengthen the view that the lowest dose of
insulin (2 µ/U/kg) inherently accelerated SIT without the
involvement of hypoglycaemia and endogenous insulin
levels in normal mice.
Our subsidiary experiment about in vitro effect of insulin
on mouse ileal longitudinal smooth muscle indicated that
all the dose ranges of insulin (2, 20, 200 µ, 2, 20, 200 m
and 2 U) tested, a marked increase in tonus of the muscle
was produced. The available literature indicates that insu-
lin produces a transitory inhibition followed by marked
increase in tonus in the gastrointestinal smooth muscle
[23]. Our results also indicate a similar phenomenon that
is an increase in tonus but without transitory inhibition at
all the ranges of insulin doses. This finding suggest a con-
vincing evidence for the myogenic effect of insulin on ileal
smooth muscle.
In this study, an excellent intestinal motor response to
insulin administration was obtained with the lower doses
of insulin (2 µ and 2 m U/kg) without the influence the
blood glucose levels. It is known that muscle contraction
is dependent upon its ability to utilize glucose [28]. Thus,
the ability of intestinal muscle to utilize glucose might
have been facilitated by insulin administration resulting
in the observed acceleration of SIT. However, a centrally
mediated hypoglycaemic effect may not be ruled out for
the acceleratory effect on intestine with the higher dose of
insulin (2 U/kg) [23].
Conclusion
The lowest dose of insulin (2 µU/kg) which accelerated
the small intestinal transit in healthy animals is without
any significant changes in the blood glucose, endogenous
insulin and C-peptide levels. It may be solely attributed to
the inherent effect of insulin which is independent of its
hypoglycaemic response. Further studies are required in
diabetic animals to explore the acceleratory effect of insu-
lin in relieving constipation.
Methods
Animals
Randomly bred normal adult Swiss albino male mice,
weighing between 20–25 g were obtained from central
animal house, JIPMER, Pondicherry. One week before the
study, animals were housed at departmental animal
house in polypropylene cages under standard laboratory
conditions. Later, animals were divided into eight groups
(n = 6). Experiments were performed during the day (9
am to 6 pm). The experimental protocol was approved by
JIPMER institutional animal ethics committee.
Drugs and chemicals
Insulin injection I.P (purified bovine insulin, 40 U/ml;
Knoll Pharmaceuticals Ltd, Aslai; India), Wood charcoal
from SD Fine Chemicals, Boisar, Gum Acacia IP from
Hikasu Chemicals, Mumbai, were used. Radio-immuno
Assay kit for insulin estimation was obtained from BRIT,
BARC, Mumbai, India, Radio-immuno Assay kit for C-
peptide of insulin estimation was procured from Diagnos-
tic Systems Laboratories, Inc, Texas, USA. Insulin injection
was diluted with normal saline solution for obtaining a
suitable strength.BMC Pharmacology 2006, 6:4 http://www.biomedcentral.com/1471-2210/6/4
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Measurement of blood glucose (BG) Levels
The Blood glucose level was measured by placing a drop
of blood obtained by venipuncture of tail, over an appro-
priate glucostix, read by Advantage Glucometer (Boer-
hinger Mannheim Corporation, Indianapolis, USA) and
expressed as %, change in the glucose level considering
the initial value of that animal as 100. The blood glucose
measurement is based on bioamperometry, the enzyme
glucose dehydrogenase present in the test strip converts
the glucose in the drop of blood to gluconolactone. This
reaction creates a harmless electrical current that the meter
interprets as blood sugar. This estimation was done 10
min before insulin administration and 2–3 min before
sacrificing the animal for measuring small intestinal tran-
sit (Fig 1).
Measurement of small intestinal transit (SIT)
The SIT was determined by identifying leading front of
intragastrically administered marker in small intestine of
an animal [12]. Charcoal meal marker was freshly pre-
pared by dispersing 10 g of wood charcoal in 5% gum Aca-
cia mucilage in purified water. Each mouse received 0.3
ml of this suspension intragastrically (i.g) using metallic
oral cannula. After 20 min animals were sacrificed by
intravenous administration of sodium pentobarbital (100
mg/kg), abdomen was cut open, the leading front of
marker was identified in the small intestine and tied
immediately to avoid movement of marker. The entire
length of small intestine was isolated by cutting at pyloric
and ileocaecal ends. The distance travelled by charcoal
meal and the total length of the intestine were measured
in cm(s). The SIT was expressed as percentage (%) of the
distance travelled by the charcoal meal to length of the
intestine. This was done in animals 50 min after insulin
administration (Fig 1).
Measurement of serum insulin and C-peptide of insulin
Serum insulin or C-peptide was measured by collecting 1
ml of blood by rupturing orbital plexus and the serum was
separated by centrifuging at 1000 g and stored at -20°C
till the assay of insulin was performed. Serum insulin or
C-peptide was estimated by radio-immuno assay (RIA)
technique [13] on a Wallac OV-20101 Wizard Automatic
Gamma Counter, Turku, Finland. This measurement was
done independently but at the time coinciding with SIT
measurement (Fig 1). Different groups of animals were
used for estimating serum insulin or C-peptide. The inter-
assay coefficient of variation of Radio-immuno assay kit
for insulin estimation (RIAK-1) was reported as less than
15 %, and intra-assay coefficient of variation was reported
as less than 10 %. The inter-assay coefficient of variation
of C-peptide RIA kit (DSL-7000) of 5 duplicates was
reported as 2.4 %, and intra-assay coefficient of variation
of 10 duplicates reported as 3.3 %.
Administration of Insulin
Each group of overnight fasted mice was administered
insulin subcutaneously (s.c) 2 µ, 2 m (milli) and 2 Units/
kg or vehicle (Fig 1). Blood glucose level was recorded
before insulin administration. Charcoal meal was admin-
istered (i.g) 30 min after insulin administration and SIT
was determined after 50 min.
Four separate groups of animals were treated similarly
without SIT measurement but one ml of blood was col-
lected through orbital plexus at the time coinciding with
SIT measurement for the measurement of serum insulin
or C-peptide levels.
Statistical analysis
Results are expressed as mean ± SEM and analysed statis-
tically using ANOVA followed by Dunnett's multiple
comparisons test. P < 0.05 was considered as statistically
significant.
Abbreviations
BG: Blood glucose; DM: Diabetes Mellitus; GI: Gastroin-
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